Download PDF
Semin intervent Radiol 2010; 27(4): 384-390
DOI: 10.1055/s-0030-1267852
© Thieme Medical Publishers

Chemotherapy Agents: A Primer for the Interventional Radiologist

Frank Mihlon1 , Charles E. Ray1 , Wells Messersmith2
  • 1Division of Interventional Radiology, Anshutz Medical Campus, Aurora, Colorado
  • 2Medical Oncology, University of Colorado Denver, Anshutz Medical Campus, Aurora, Colorado
Further Information

Publication History

Publication Date:
19 November 2010 (online)

Also available at
    Permissions and Reprints

ABSTRACT

In this article, the authors review the basic principles of cancer chemotherapy and provide an overview of each of the general classes of chemotherapeutic agents with a target audience of interventional radiologists in mind. Special attention is paid to agents used in regional chemotherapy as well as agents commonly included in systemic chemotherapeutic regimens for patients who also require regional chemotherapy.

KEYWORDS

Regional chemotherapy - principles of chemotherapy - cancer chemotherapy - chemotherapy review - chemotherapy agents

REFERENCES

  • 1 Howard A, Pelc S R. Nuclear incorporation of P32 as demonstrated by autoradiographs.  Exp Cell Res. 1951;  2(2) 178-187
    CrossrefPubMedGoogle Scholar
  • 2 Reed S. Cell cycle. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 83
    Google Scholar
  • 3 Lees J. Control of the cell cycle. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W Abeloff's Clinical Oncology. 4th ed. Philadelphia; Churchill Livingstone/Elsevier 2008: 50
    Google Scholar
  • 4 Norton L. A Gompertzian model of human breast cancer growth.  Cancer Res. 1988;  48(24 Pt 1) 7067-7071
    PubMedGoogle Scholar
  • 5 Goldie J H, Coldman A J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.  Cancer Treat Rep. 1979;  63(11-12) 1727-1733
    PubMedGoogle Scholar
  • 6 Kinsella A R, Smith D. Tumor resistance to antimetabolites.  Gen Pharmacol. 1998;  30(5) 623-626
    CrossrefPubMedGoogle Scholar
  • 7 Ray C, Koczwara B. Principles of chemotherapy. In: Ray CE, Hicks ME, Patel NH Interventions in Oncology. Fairfax VA; Society of Interventional Radiology 2003: 9-15
    Google Scholar
  • 8 Huitema A D, Smits K D, Mathôt R A, Schellens J H, Rodenhuis S, Beijnen J H. The clinical pharmacology of alkylating agents in high-dose chemotherapy.  Anticancer Drugs. 2000;  11(7) 515-533
    CrossrefPubMedGoogle Scholar
  • 9 Hirsch J. An anniversary for cancer chemotherapy.  JAMA. 2006;  296(12) 1518-1520
    CrossrefPubMedGoogle Scholar
  • 10 Kummar S, Noronha V, Chu E. Antimetabolites. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 358
    Google Scholar
  • 11 Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs.  Br J Clin Pharmacol. 1999;  47(2) 131-143
    CrossrefPubMedGoogle Scholar
  • 12 Rowinsky E, Tolcher A. Antimicrotubule agents. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 390-411
    Google Scholar
  • 13 Verstappen C C, Koeppen S, Heimans J J et al.. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.  Neurology. 2005;  64(6) 1076-1077
    CrossrefPubMedGoogle Scholar
  • 14 Takimoto C. Topoisomerase interactive agents. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 375-389
    Google Scholar
  • 15 Colvin O, Friedman H. Alkylating agents. In: DeVita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 332-344
    Google Scholar
  • 16 Copur M, Rose M, Chu E. Miscellaneous chemotherapeutic agents. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 417
    Google Scholar
  • 17 Gately D P, Howell S B. Cellular accumulation of the anticancer agent cisplatin: a review.  Br J Cancer. 1993;  67(6) 1171-1176
    CrossrefPubMedGoogle Scholar
  • 18 Johnson S, O'Dwyer P. Cisplatin and its analogues. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 344-358
    Google Scholar
  • 19 Ito Y, Sasaki Y, Horimoto M et al.. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.  Hepatology. 1998;  27(4) 951-958
    CrossrefPubMedGoogle Scholar
  • 20 Llovet J M, Ricci S, Mazzaferro V SHARP Investigators Study Group et al. Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;  359(4) 378-390
    CrossrefPubMedGoogle Scholar
  • 21 Sondak V, Redman B. Pharmacology of cancer biotherapeutics. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 423-430
    Google Scholar
  • 22 Mier J, Atkins M. Interleukin-2. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 431-438
    Google Scholar
  • 23 Marks P, Richon V, Miller T, Kelly W. Histone deacetylase inhibitors: new targeted anticancer drugs. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 439-445
    Google Scholar
  • 24 Cheng J, Adams G, Robinson M, Weiner L. Monoclonal antibodies. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 445-456
    Google Scholar
  • 25 Goetz M, Erlichman C, Loprinzi C. Pharmacology of endocrine manipulation. In: De Vita V, Hellman S, Rosenberg S Cancer: Principles & Practice of Oncology. Philadelphia; Lippincott Williams & Wilkins 2005: 457-469
    Google Scholar

Charles RayM.D. 

23765 Currant Drive

Golden, CO 80401

Email: charles.ray@ucdenver.edu